São Paulo, March 2020 – Eurofarma, a Brazilian multinational with its own operations in 20 Latin American countries, has signed an agreement to purchase Hypera Pharma assets, recently acquired from Takeda for the markets of the region, with the exception of Brazil.
There are 12 drugs in all, including own and licensed, over-the-counter and prescription, which total UDS 38 million in sales.
The decision is in line with the organization’s strategic plan for the purpose of Eurofarma becoming a strong regional competitor and with the goal of international revenues representing 30% by 2022. It also contributes to expanding the company’s exclusive portfolio, since some products are protected by patent.
“The acquisition is in line with our international expansion strategy through acquisitions and this is also a major step towards having a robust platform in Mexico, the second largest market in the region”, says Maria Del Pilar Muñoz, vice president of Sustainability and New Business.
Mexico, the main target market, accounts for 95% of sales for the acquired portfolio. There, the agreement stipulates that Eurofarma will absorb part of Takeda’s commercial team, consisting of approximately 80 employees working in medical advertising.
With a lesser representation, the transaction includes assets in Argentina, Ecuador, Mexico, Panama and Peru, with emphasis on Neosaldina in Colombia.
The completion of this transaction depends on regulatory authority approval.
About Eurofarma Group
Eurofarma is a health company focused on offering products and services to improve people’s lives with quality, innovation and fair prices across all major pharmaceutical segments: Prescription, Generic, Hospital, Oncology, and Nonprescription Drugs, as well as Veterinary Medicine. In Brazil alone, the company offers 287 different molecules and over 600 products. Eurofarma is a leader in medical prescriptions, serving 30 different specialties and covering 101 therapeutic classes, which account for 89% of retail pharmaceutical sales. The company has the largest sales force in the country, which visits approximately 600,000 doctors monthly.
Founded in 1972 and the first pharmaceutical multinational with 100% Brazilian capital, it has own operations in 20 countries and maintains a major manufacturing park in Brazil, as well as plants in 6 other Latin American countries. The Group reported sales of BRL 5.4 billion in 2019 and employs over 7,000 employees.